ExonHit Eyes Affy Platform for Alzheimer’s Test; Could Launch Dx As Early As 2009 | GenomeWeb
French diagnostics firm ExonHit Therapeutics said last week that it has developed a prototype based on the Affymetrix GeneChip Platform for a blood-based test to identify patients suffering from Alzheimer’s disease.
ExonHit said it expects it to have the test certified and ready to market as early as 2009, placing it on a similar timeline as several firms that have committed to developing diagnostics on the Affy platform, including BioMérieux, Roche Diagnostics, Epigenomics, Almac Diagnostics, and others.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.